Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT04205994

Dopaminergic Mechanisms Underlying Human Social Behavior

Dopaminergic Mechanisms Underlying Human Social Behavior: A Multimodal Approach

Sponsor: Lawrence Berkeley National Laboratory

Conditions Decision Making Dopamine Executive Function

Interventions Functional Magnetic Resonance Imaging (fMRI) Tolcapone 200 MG

Updated 7 times since 2020 Last updated: May 14, 2024 Started: Dec 1, 2019 Primary completion: Dec 31, 2023 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Decision Making and Dopamine and is currently completed. Lawrence Berkeley National Laboratory leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jun 2024 — Jul 2024 [monthly]

Completed EARLY_PHASE1

Status: Recruiting → Completed
Sep 2022 — Jun 2024 [monthly]

Recruiting EARLY_PHASE1
Feb 2022 — Sep 2022 [monthly]

Recruiting EARLY_PHASE1

▶ Show 2 earlier versions

Jan 2021 — Feb 2022 [monthly]

Recruiting EARLY_PHASE1
Jan 2020 — Jan 2021 [monthly]

Recruiting EARLY_PHASE1

First recorded

Dec 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lawrence Berkeley National Laboratory
University of California, Berkeley
University of California, San Francisco

Data source: University of California, Berkeley

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berkeley, United States